CD44v6 expression in primary breast carcinoma in western India: A pilot clinicopathologic study

Tumori

Volumn 96, Issue 6, 2010, Pages 971-977

  Shah, Neelam G ^a   Trivedi, Trupti I ^a   Vora, Hemangini H ^a   Patel, Kinjal C ^a   Tankshali, Rajen ^a   Goswami, Jignesh V ^a   Shukla, Shilin N ^a   Shah, Pankaj M ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Breast cancer; CD44v6; Clinicopathologic parameters; Prognosis

Indexed keywords

CD44V ANTIGEN; CD44V10 ANTIGEN; CD44V6 ANTIGEN; CD44V9 ANTIGEN; HERMES ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PILOT STUDY; PROGNOSIS; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

EID: 79551488994     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/548.6518     Document Type: Article

References (30)

1. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, Trivedi TI: Prognostic significance of immunohistochemically localised biomarkers in stage II and stage III breast cancer: A multivariate analysis. Ann Surg Oncol, 7: 305-311, 2000.
2. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65: 13-24, 1991.
3. Rudy W, Hofmann M, Schwartz-Albiez R, Zoller M, Heider K-H, Ponta H, Herrlich P: The twomajor CD44 proteins expressed on ametastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behaviour. Cancer Res, 53: 1262-1268, 1993.
4. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol, 143: 867-874, 1993.
5. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe H-J, Holzel F, Maass H, Gunthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res, 5: 5424-5433, 1995.
6. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345: 615-619, 1995.
7. th ed, John Wiley and Sons, Inc, New York, 1997.
8. le Doussal V, Tubiana-Hulin M, Freidmans S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinoma. Cancer, 64: 1914-1921, 1989.
9. Bhatavdekar JM, Patel DD, Chikhlikar PR, Trivedi TI, Gosalia NM, Ghosh N, Shah NG, Vora HH, Suthar TP, Doctor SS: Overexpression of CD44: A useful independent predictor of short-term prognosis in patients with colorectal carcinoma. Ann Surg Oncol, 5: 495-501, 1998.
10. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem, 162: 156-159, 1987.
11. Dall P, Heider KH, Sinns HP, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P, Ponta H: Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer, 60: 471-477, 1995.
12. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR, Trupti TI: Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol, 26: 540-547, 2000.
13. Naor D, Sionov RV, Ish-Shalom D: CD44: structure, function, and association with themalignant process. Adv Cancer Res, 71: 241-319, 1997.
14. Tempfer C, Losch A, Hausler G, Heinzl H, Kolbl H, Breitemmecker G, Kainz C: Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-v8 in human breast cancer. Eur J Cancer, 32A: 2023-2025, 1996.
15. Tokue Y, Matsumura Y, Katsumata N, Watanabe T, Tarin D, Kakizoe T: CD44 variant isoform expression and breast cancer prognosis. Jpn J Cancer Res, 89: 283-290, 1998.
16. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM: Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology, 47: 420-428, 2005.
17. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ: CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res, 11: 3309-3314, 2005.
18. Ma W, Deng Y, Zhou L: The prognostic value of adhesion molecule CD44v6 in women with primary breast cancer: a clinicopathologic study. Clin Oncol (R Coll Radiol), 4: 258-263, 2005.
19. Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF: Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol, 16: 121-127, 2008.
20. Berner HS, Nesland JM: Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast. Breast Cancer Res Treat, 65: 23-29, 2001.
21. Bànkfalvi À, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lellè RJ, Böcker W: Gains and losses of CD44 expression during breast carcinogenesis and tumor progression. Histopathology, 33: 107-116, 1998.
22. Woodman AC, Sugiyama M, Yoshida K, Sugini T, Borgaya A, Goodison S, Matsumura Y, Tarin D: Analysis of anomalous CD44 gene expression in human breast, bladder and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol, 149: 1519-1530, 1996.
23. Altieri DC: Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron. Biochemistry, 33: 13848-13855, 1994.
24. van Leusden MR, Kuikman I, Sonnenberg A: The unique cytoplasmic domain of the human integrin variant beta4E is produced by partial retention of intronic sequences. Biochem Biophys Res Commun, 235: 826-830, 1997.
25. Ebihara K, Masuhiro Y, Kitamoto T, Suzawa M, Uematsu Y, Yoshizawa T, Ono T, Harada H, Matsuda K, Hasegawa T, Masushige S, Kato S: Intron generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway. Mol Cell Biol, 16: 3393-3400, 1996.
26. Caceres JF, Stamm S, Helfman DM, Krainer AR: Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science, 256: 1706-1709, 1994.
27. Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG, Nesland JM: Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology, 42: 546-554, 2003.
28. Soukka T, Salmi M, Joensuu H, Hakkinen L, Sointu P, Koulu L, Kalimo K, Klemi P, Grenman R, Jalkanen S: Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res, 57: 2281-2299, 1997.
29. Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I, Yajima A: Expression of CD44 in normal versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res, 54: 3922-3925, 1994.
30. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW: Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett, 89: 81-87, 1995.